Warfarin-related nephropathy is the tip of the iceberg: Direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats

Nephrology Dialysis Transplantation

Volumn 29, Issue 12, 2014, Pages 2228-2234

  Ryan, Margaret ^a   Ware, Kyle ^a   Qamri, Zahida ^a   Satoskar, Anjali ^a   Wu, Haifeng ^a   Nadasdy, Gyongyi ^a   Rovin, Brad ^b   Hebert, Lee ^b   Nadasdy, Tibor ^a   Brodsky, Sergey V ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Dabigatran; Warfarin related nephropathy

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; CREATININE; DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; ERYTHROCYTE; GLOMERULAR HEMORRHAGE; GLOMERULOPATHY; HEMATURIA; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MALE; MORPHOLOGY; NEPHRECTOMY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; WARFARIN RELATED NEPHROPATHY; ANALOGS AND DERIVATIVES; ANIMAL; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GLOMERULUS; KIDNEY; PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ACUTE KIDNEY INJURY; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; DISEASE MODELS, ANIMAL; HEMORRHAGE; KIDNEY; KIDNEY GLOMERULUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; WARFARIN;

EID: 84928704225     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft380     Document Type: Article

References (31)

1. Brodsky SV, Satoskar A, Chen J et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 2009; 54: 1121-1126
2. Brodsky SV, Collins M, Park E et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010; 115: c142-c146
3. Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80: 181-189
4. Ozcan A, Ware K, Calomeni E et al. 5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol 2012; 35: 356-364
5. Ware K, Brodsky P, Satoskar AA et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol 2011; 22: 1856-1862
6. Kadiyala D, Brewster UC, Moeckel GW. Dabigatran induced acute kidney injury. In: The American Society of Nephrology Annual Meeting, November 1-4, 2012, FR-PO1122, San Diego, CA, 2012
7. Committee for the Update of the Guide for the Care Use of Laboratory Animals National Research Council Guide for the Care and Use of Laboratory Animals, 8th edn. The National Academies Press, 2011, Washington, DC
8. Manaenko A, Sun X, Kim CH et al. PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats. Neurobiol Dis 2013; 50: 13-20
9. El Eter EA, Aldrees A. Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury. Shock 2012; 37: 639-644
10. Berry CN, Lunven C, Girardot C et al. Ecarin clotting time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat. Thromb Haemost 1998; 79: 228-233
11. Wienen W, Stassen JM, Priepke H et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007; 98: 333-338
12. Wienen W, Stassen JM, Priepke H et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-162
13. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295
14. Stangier J, Stahle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59
15. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399
16. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43: 682-692
17. Gosselin RC, King JH, Janatpour KA et al. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38: 1383-1388
18. Spinler S. The pharmacology and therapeutic use of dabigatran etexilate. J Clin Pharmacol 2013; 53: 1-13
19. Kamboj J, Kottalgi M, Cirra VR et al. Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing 'guidelines' in overdose and to find an 'antidote'! Am J Ther 2012; 19: e182-e185
20. Perez A, Eraso LH, Merli GJ. Implications of new anticoagulants in primary practice. Int J Clin Pract 2013; 67: 139-156
21. Maddry JK, Amir MK, Sessions D et al. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med 2013; 31: 462. e1-462.e2
22. Bene J, Said W, Rannou M et al. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother 2012; 46: e14
23. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46: e10
24. Woo JS, Kapadia N, Phanco SE et al. Positive outcome after intentional overdose of dabigatran. J Med Toxicol 2013; 9: 192-195
25. Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013; 93: 68-77
26. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814
27. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001; 86: 298-307
28. Carlile-Klusacek M, Rizzo V. Endothelial cytoskeletal reorganization in response to PAR1 stimulation is mediated by membrane rafts but not caveolae. Am J Physiol Heart Circ Physiol 2007; 293: H366-H375
29. Rondeau E, Vigneau C, Berrou J. Role of thrombin receptors in the kidney: lessons from PAR1 knock-out mice. Nephrol Dial Transplant 2001; 16: 1529-1531
30. Xu Y, Zacharias U, Peraldi MN et al. Constitutive expression and modulation of the functional thrombin receptor in the human kidney. Am J Pathol 1995; 146: 101-110
31. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med 2011; 49: 755-757